Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-09
2011-08-09
Chang, Celia (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S479000
Reexamination Certificate
active
07994327
ABSTRACT:
The present invention provides new processes for the preparation of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds which are useful, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-α. The invention can provide improved and/or efficient processes for the commercial production of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds, including, but not limited to, unsubstituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
REFERENCES:
patent: 5134127 (1992-07-01), Stella et al.
patent: 5463063 (1995-10-01), Muller
patent: 5635517 (1997-06-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6114355 (2000-09-01), D'Amato
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6458810 (2002-10-01), Muller et al.
patent: 6476052 (2002-11-01), Muller et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 7041680 (2006-05-01), Muller et al.
patent: 7091343 (2006-08-01), Bebbington et al.
patent: 7153867 (2006-12-01), Shah et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 2004/0220144 (2004-11-01), Zeldis
patent: 2005/0096351 (2005-05-01), Jaworsky et al.
patent: 2005/0203142 (2005-09-01), Zeldis et al.
patent: 2006/0004054 (2006-01-01), Zeldis
patent: 2006/0025457 (2006-02-01), Muller et al.
patent: 2006/0052609 (2006-03-01), Muller et al.
patent: 2006/0069065 (2006-03-01), Zeldis
patent: 2006/0084815 (2006-04-01), Muller et al.
patent: 2007/0049618 (2007-03-01), Muller et al.
patent: 2008/0214615 (2008-09-01), Muller et al.
patent: 858 086 (1961-01-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 00/55134 (2000-09-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 2005/005409 (2005-01-01), None
patent: WO 2009/111948 (2009-09-01), None
patent: WO 2009/114601 (2009-09-01), None
Braga et al. “Making crystals from crystals . . . ” J. roy. soc. Chem. chem. Commun. p. 3635-3645 (2005).
Kirk-Othmer “encyclopedia of chemical tech . . . ” vol. 8, p. 96-147 (2002).
Muller et al. “Preparation of 1-oxo and 1,3,-dioxol . . . ” CA 133:252302 (2000).
Sun et al. “The inhibitory effects of . . . ” CA 62:93681 (1965).
Miyachi et al. “Tumor necrosis . . . ” CASREACT 129:216494 (1998).
Miyachi et al. “Tumor nicrosis . . . ” Chem. Pharm. Bull. v.46(7) 1165-1168 (1998).
Gutzwiller “aryl thio . . . ” CA43:42732 (1949).
CA51:86009 (1957).
Capitosti et al., “Facile synthesis of an azido-labeled thalidomide analogue,” Org Lett. Aug. 7, 2003;5(16):2865-7.
Chang et al., “A synthesis of racemic thalidomide,” Synthetic Communications 2003;33(8):1375-82.
Corral et al., “Immunomodulation by thalidomide and thalidomide analogues,” Ann Rheum Dis. 1999;58(Suppl. 1):I107-13.
Dezube et al., “Pentoxifylline and wellbeing in patients with cancer,” Lancet 1990;335(8690):662.
Eger et al., “Synthesis, Central nervous system activity and teratogenicity of a homothalidomide,” Arzneimittelforschung Oct. 1990;40(10):1073-5.
Glogau, “The risk of progression to invasive disease,” J Am Acad Dermatol. 2000;42(1 Pt 2):S23-4.
Goette, “Topical chemotherapy with 5-fluorouracil. A review,” J Am Acad Dermatol. Jun. 1981;4(6):633-49.
U.S. Appl. No. 60/518,600, filed Nov. 6, 2003, Zeldis.
U.S. Appl. No. 60/554,923, filed Mar. 22, 2004, Zeldis et al.
Gutschow et al., Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro. Bioorg Med Chem. Apr. 2001;9(4):1059-65.
He et al., “Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host diseases,” 206th American Chemical Society, Chicago, IL, Med Chem paper 1993;216.
Hess et al., “Synthesis and immunological activity of water-soluble thalidomide prodrugs,” Bioorg Med Chem. May 2001;9(5):1279-91.
Hinshaw et al., “Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha),” Circ Shock. Mar. 1990;30(3):279-92.
Jonsson et al., “Chemical structure and teratogenic properties: 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogs,” Acta Pharm Suec. Dec. 1972;9(6):521-42.
Klinsberg, Erwin,Chemistry of Heterocyclic Compounds, New York, Wiley & Sons 1960:295-6.
Lima et al., “Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues,” Bioorg Med Chem. Sep. 2002;10(9):3067-73.
Luzzio et al., “Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutarimide. A metabolite of thalidomide isolated from human plasma,” J Org Chem. Nov. 25, 2005;70(24):10117-20.
Luzzio et al., “Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S(3-hydroxy) ornithine,” Tetrahedron Lett. 2000, 41:7151-55.
Luzzio et al., “Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine,” J Med Chem. Aug. 28, 2003;46(18):3793-9.
Luzzio et al., “Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-γ-hydroxyglutamic acid,” Tetrahedron Letters 2000; 41:2275-8.
Luzzio et al., “Thalidomide analogues: derivatives of an orphan drug with diverse biological activity,” Expert Opin Ther Patents 2004;14(2):215-29.
Machado et al., “Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide,” Bioorg Med Chem Lett. Feb. 15, 2005;15(4):1169-72.
Man et al., “Alpha-fluoro-substituted thalidomide analogues,” Bioorg Med Chem Lett. Oct. 20, 2003;13(20):3415-7.
Marks et al., “Malignant transformation of solar keratoses to squamous cell carcinoma,” Lancet Apr. 9, 1988;1(8589):795-7.
Millar et al., “Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome,” Lancet Sep. 23, 1989;2(8665):712-4.
Muller et al., “A concise two-step synthesis of thalidomide,” Organic Process Research & Development 1999;3:139-40.
Muller et al., “Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production,” Bioorg Med Chem Lett. Jun. 7, 1999;9(11):1625-30.
Muller et al., “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity,” J Med Chem. Aug. 16, 1996;39(17):3238-40.
Muller et al., “Thalidomide analogs and PDE4 inhibition,” Bioorg Med Chem Lett. Oct. 6, 1998;8(19):2669-74.
Mureil et al., “Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimide-3-(3,4-dimethoxyphenyl)-propanioc acid in liver cirrhosis induced by bile duct ligation in the rat,” Hepatology 2001 34(4):517A, Abastract#1379.
Noguchi et al., “Angiogenesis inhibitors derived from thalidomide,” Bioorg Med Chem Lett. De
Chen Roger
Ge Chuansheng
Muller George W.
Saindane Manohar Tukaram
Celgene Corporation
Chang Celia
Jones Day
LandOfFree
Processes for the preparation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processes for the preparation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for the preparation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776944